Every 424B that Lexaria Bioscience Corp. (LEXX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LEXX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LEXX filings page.
Lexaria Bioscience Corp. is registering up to 2,754,756 shares of common stock for resale by existing investors. These shares are issuable upon the exercise of outstanding warrants from a December 2025 private placement and related placement agent compensation. The company will not receive any money from stockholders’ resale of these shares.
If the warrants are exercised for cash, Lexaria would receive approximately $3.3 million in gross proceeds, which it plans to use for research and development, working capital and general corporate purposes. The company had 24,887,446 shares outstanding as of December 26, 2025, and its stock trades on the Nasdaq Capital Market under the symbol “LEXX”, with a last reported price of $0.809 per share on January 13, 2026.
Lexaria Bioscience Corp. is offering 2,661,600 shares of common stock at $1.315 per share in a primary registered direct sale to institutional investors. Gross proceeds are expected to be $3,500,004.00, with net proceeds of about $3.0 million after placement fees and expenses, which the company plans to use to advance research and development, fund working capital and for other general corporate purposes.
Alongside the stock sale, Lexaria is issuing in a separate private placement warrants to purchase up to 2,661,600 additional shares at an exercise price of $1.19 per share. If all of these private placement warrants are exercised for cash, the company would receive roughly $3.1 million in additional net proceeds.
Shares outstanding were 22,225,846 as of December 14, 2025 and are expected to become 24,887,446 after this offering, excluding any warrant or option exercises. Based on a pro forma as adjusted net tangible book value of $0.35 per share as of August 31, 2025, investors buying in this offering face immediate dilution of $0.97 per share, and the company highlights risks related to stock price volatility, Nasdaq listing compliance and potential future dilution.
Lexaria reports clinical study signals for its DehydraTECH oral delivery platform showing several enhanced formulations outperformed the oral GLP-1 control Rybelsus® on 12-week body weight control and body-weight improvement, with statistically significant advantages by week 12 for most enhanced arms. Specific arms showed blood sugar changes: DehydraTECH-liraglutide (Group H) -11.540%, and select DehydraTECH-CBD arms Group A 1.09% and Group B -3.76%. Pharmacokinetic results for DehydraTECH-tirzepatide showed fewer adverse events than injected Zepbound®, lower but steadier blood levels that reached parity with Zepbound by study end. The study reached last patient last visit on August 14, 2025, enabling full sample and data analyses toward a late-2025 final report. DehydraTECH is described as a drug-delivery platform combining APIs with long-chain fatty acid-rich triglyceride oils and carriers to improve oral absorption and tolerability.